|ANNUAL REPORT CONTENTS|||
|---|---|---|
|INTRODUCTION|||
|TRUSTEES' REPORT INCORPORATING|THE STRATEGIC REPORT||
|STATEMENT OF RESPONSIBILITIES OF|THE TRUSTEES OF JOHN INNES CENTRE IN||
|RESPECT OF THE TRUSTEES' ANNUAL|REPORT AND THE FINANCIAL STATEMENTS|19|
|INDEPENDENT
AUDITOR'S REPORT TO THE MEMBERS OF THE JOHN INNES CENTRE||20|
|FINANCIAL STATEMENTS||23|
|NOTES TO THE ACCOUNTS||26|
|CHARITY INFORMATION||43|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|STAKEHOLDER ENGAGEMENT —SECTION 172STATEMENT|
|---|---|---|---|---|---|---|
|The Trustee|Directors consider that the decisions they have||||made during
the financial year have satisfied the||
|requirements||ofs172(1)ofthe Companies
Act 2006 and that they have acted in good faith to promote the success|||||
|ofJICas a|whole, and
in doing so having
regard to the stakeholders
and matters
outlined
in s172(1).||||||
|The Governing||Council has the ultimate
responsibility
for|the||strategy ofJIC and delivery of its charitable||
|objectives.|The table below sets out JIC's most significant|||stakeholders,
why they are considered
important
and|||
|how the Institute engages.|||||||
|||&We are committed
to providing
a||||&During the year, regular communications
to|
|||supportive,
inspirational
and dynamic||||employees
have been provided
on matters|
|||environment
for our staff and students||to||affecting them,
including
factors affecting|
|||meet future scientific and societal||||the Charity's
progress,
and have been|
|||challenges.||||consulted
on decisions that impact them.|
|||kWe value the diversity ofour staff, and||||k All groups ofstaff and students
have|
|||are committed
to the creation ofa||||representation
on the Inclusivity
8 Diversity|
|||positive environment
which is fair,||||Committee
that meets 4times a year to|
|||welcoming
and inclusive
and where||||ensure an inclusive
research culture|
|||everyone
is treated
with dignity and||||&Students'
progress
is monitored
on a|
|||respect.||||regular basis and employees
undertake
an|
|||&We are committed
to the development|||of|annual
appraisal
where their training
needs,|
|||all our staff and students
and providing||||work-life balance and career development|
|||equal opportunities
that encourage||||are discussed.|
|||flexible working, career development||and|||
|||work-life balance.|||||
|||&JIG's corporate
members
are UK||||&The Members each nominate
one|
|||Research and Innovation
(UKRI); John||||Governing
Council member
and appoint|
|||Innes Foundation
(JIF);and the||||one "observer" to attend
Governing
Council|
|||University
ofEast Anglia (UEA). Our||||meetings,
enabling
them to participate
in|
|||members
are key strategic partners|that|||key decisions.|
|||oversee our delivery against charitable|||||
|||objectives.|||||
|||kJIC is one of4 independent,
world-class||||k The Institute
Directors ofthe 4 institutes|
|||research
institutes
based at the Norwich||||meet regularly
to discuss common strategic|
|||Research Park. The Institutes
work||||and operational
matters.|
|||closely together to create a unique centre||||&JIC, the other Institutes,
UKRI, UEA, JIF|
|||ofexcellence
in plant and microbial||||and the N8 NU Hospital Trust are members|
|||sciences, big data science and||||ofAnglia
Innovation
Partnership
LLP, an|
|||genomics,
and food and health.||||organisation
established
to promote|
|||||||collaborative
solutions to global challenges|
|||||||in food and health.|
|||&JIG is strategically
funded,
along with||7||&UKRI nominates
a Governing
Council|
|||other institutes,
by the Biotechnology||and||member
and appoints
an "observer" to|
|||Biological Sciences Research Council||||attend
Governing
Council meetings.|
|||(BBSRC),part of UKRI. BBSRC||||&JIC holds regular meetings
with BBSRCto|
|||supports JIC via strategic 5-year funding||||review and progress ofthe Institute's|
|||programmes,
competitively
won project||||mission and science programmes,
including|
|||grants
and capital funding
for||||strategic and financial
plans.|
|||infrastructure
and technology|||||
|||investments.|||||
|||&JIC is an international
centre of plant||and||&An extensive
programme
ofengagement|
|||microbial research. Our success is built||||with our new collaborative
vision, Healthy|
|||on our collaborations
and our||||Plants, Healthy People, Healthy
Planet|
|||international
outlook.||||(HP3) is ongoing
and involves discussion,|
|||&JIC is home to a range ofstate-of-the-art||||input and views from stakeholders
from|
|||facilities and technology
platforms
to||||industry,
government
and research|
|||support scientists across the UK.||||partners,
locally, nationally
and|
|||||||internationally.
JIC has strategic|
|||||||partnerships
with research and academic|
|||||||institutions
in the UK and worldwide,|
|||||||including
Europe, China, Africa, Brazil and|
|||||||India.|
|&JIG works closely with|&JIG works closely with|industry|industry|and the|&JIG maintains
a dialogue
with industry,
with|
|---|---|---|---|---|---|
|private sector|to provide access to our||||regular consultations
and knowledge|
|capabilities,
and to deliver|||sophisticated||exchange.|
|interdisciplinary|research||and product||&JIG supports
industry
through
collaborative|
|development|at pace.||||and sponsored
research
and access to its|
||||||facilities and plafform services. JIC is|
||||||proactive
in identifying
and responding
to|
||||||industry
need.|
||||||&JIG protects
its innovations
and promotes|
||||||their commercialisation
and adoption
by|
||||||Industry.|
||||||&JIF nominates
an industry
representative
as|
||||||an "observer" to attend
Governing
Council|
||||||meetings.|
|&Public views are at the heart of||||our|&JIC staff and students
are trained
in public|
|research strategy
and||engaging||with the|engagement
and communications
and are|
|public is an important||part|ofour mission||supported
to attend events, use digital|
|statement.|||||media and to discuss and engage the public|
||||||with our research.|
||||||kJIC hosts and attends
community
events—|
||||||online,
locally and nationally,
to showcase,|
||||||debate and discuss the nature ofour|
||||||research.|
||||||&JICscientists are engaged
in policy|
||||||discussions
at a national
level surrounding|
||||||the use ofgenetic technologies
for crop|
||||||improvement.
kJIC is investing
heavily
in more energy|
||||||efficient facilities to reduce utilities|
||||||consumption
and waste.|
|&JIC seeks to maintain||and|develop||&JIC holds regular meetings
with suppliers|
|strong, open,|collaborative||relationships||about purchasing
relationships
and ethical|
|with our supply chain.|||||behaviours
such as adherence
to Modern|
||||||Slave
rinci les.|
##
|RISKASSESSMENT AND MANAGEMENT|RISKASSESSMENT AND MANAGEMENT|RISKASSESSMENT AND MANAGEMENT|RISKASSESSMENT AND MANAGEMENT|RISKASSESSMENT AND MANAGEMENT|||||
|---|---|---|---|---|---|---|---|---|
|Governing|Council is responsible
for ensuring
there||are|effective and adequate
risk management
and internal|||||
|control systems
in place and confirm that the major|||risks to which the Institute
is exposed have been reviewed||||and||
|procedures|established
to manage those risks. The Audit Committee
agrees an annual
risk-based
internal
audit||||||||
|plan which|covers major risks identified
by management|||and Trustees.
It receives reports from internal
auditors||||on|
|the effectiveness||of internal
controls, progress against the|||internal
audit plan and progress on recommendations||||
|made
in reports.||Governing
Council reviews a full risk report annually,
including
a 'heat map' tracking
major||||risks.|||
|The Science and||Impact Advisory
Board (SIAB)assess||the science quality
and vision section ofthe risk register.|||||
|Principal|risks and uncertainties||||||||
|||& BBSRCstrategic funding
is reduced||&|Regular
monitoring
ofscientific performance,
including||||
|||as a result ofpoor performance
or|||consideration
from the Science and Impact Advisory
Board.||||
|||public sector spending
pressures.||&|Regular engagement
with BBSRCto report performance||and||
|||&JIC is too reliant on BBSRCstrategic|||ensure strategic alignment
of research
programmes.||||
|||and grant funding||&|Monitoring
ofperformance
ofgrant submissions.||||
|||||&|Funding
opportunities
for other research bodies and charities||||
||||||regularly
communicated
to Group Leaders.||||
|||||&|Philanthropic
Fundraising
strategy
being developed
to support||||
||||||NGI plus strategic research activity.||||
|||& The focus ofscience programmes,|or|&|The Science Impact and Advisory
Board, comprising||||
|||balance between
discovery
and|||independent
international
experts, regularly
reviews the||||
|||translational
science, does not meet|||development
ofstrategic programmes
and JIC impact.||||
|||funders'
or stakeholders'
expectations.||k|The executive Research Committee
reviews scientific areas|||of|
|||k JIC fails to deliver the world-leading|||excellence and horizon scans to identify strategically||||
|||science|||important
scientific areas and opportunities.||||
|||&JIC is unable to retain or attract||&|Strategy and action plans
in place, overseen
by the JIC||||
|||suitably
skilled staff to enable
it to|||People &Culture Committee.||||
|||sustain
its scientific performance.||&|Career development
programmes
in place to support
high||||
|||& In addition to scientific impact, this risk|||potential
staff.||||
|||area could also have an impact on the
level offunding
the institute
is able to
attract.||&|Recruitment
strategy and processes
in place, including
attractive support arrangements.||||
|||& Increased
energy prices divert||&|Energy costs are hedged
in the short-term
and specialist||||
|||resources from science to|||advisers
support the institute
with energy procurement.||||
|||infrastructure
costs, resulting
in a
reduction
in research
activity and
impact.||&|Energy-saving
opportunities
are actively targeted
and
investment
cases developed,
aligned to net zero carbon
strategic planning.||||
|||& High inflation increases research
and
support costs, resulting
in a reduction
in research
activity and impact.||k|The impact ofcost inflation
is regularly
discussed
with funders
with a view to mitigating
the impact on research.||||
|||&Cost pressures
mean that the agreed||&|Dedicated
programme
team recruited,
supported
by JIG staff||||
|||scope cannot be delivered|||and professional
consultants||||
|||& Insufficient
additional
funding
raised||&|Governance
structure
for programme
implemented,
led|by|||
|||& Vision for NGI Hub not sufficiently|||Programme
Board and supported
by external assurance||||
|||defined or communicated||&|Workstreams
established
to define Hub vision, engage|with|||
|||& Buildings design do not reflect future|||external stakeholders
and deliver business change||||
|||science requirements
or Hub vision||&|Building design engagement
groups established||||
|||& Building works significantly
disrupt||&|Strategy developed
to deliver Net Zero Carbon ambition||||
|||science activity during
construction||&|Fundraising
plan being developed||||
|||& Project does not achieve
Net Zero|||||||
|||Carbon ambition|||||||
|||&JIC is unable to keep pace with||k|5-year investment
plan developed.||||
|||developments
in technology
underpinning
its science.||&|Funding
opportunities
identified
and pursued
for technology
investments.||||
|||& A major incident disrupts
scientific||&|Business Continuity
and Disaster recovery plans
in place||and||
|||research
programmes
or|||tested periodically.||||
|||administrative
systems.||&|Review ofcompliance
with health &safety and relevant||||
||||||regulations
from government
agencies and internal
auditors.||||
|||||&|Insurance
arrangements
in place.||||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||||||Restricted|Restricted||Restated|
|---|---|---|---|---|---|---|---|---|---|---|
|||||||Unrestricted|general|capital|Total|Total|
|||||||funds|funds|funds|2023|2022|
||||||Note|f000|FOOO|FOOO|f000|OOOO|
|Income|||||||||||
|Income from charitable|activities||||||||||
|Grant income|||||||36,893|91|36,984|34,691|
|Capital and maintenance||grants|||||831|14,093|14,924|13,420|
|Other charitable
income||||||828|||828|705|
|Income from other tradingactivities|||||||||||
|Trading
income||||||928|||928|491|
|Rental income||||||255|||255|141|
|Investment
income||||||636||||118|
|Share ofoperating result||ofassociates|||12|||||261|
|Otherincome||||||3,871|||3,871|3,121|
|Total income|||||2|6,518|37,724|14,184|58426|52,948|
|Expenditure|||||||||||
|Charitable
activities|||||3|(5,335)|(38,345)|(8,039)|(51,719)|(44,700)|
|Raising funds|||||3|(439)|-|-|(439)|(370)|
|Trading
expenditure|||||3|(692)|||(692)|(579)|
|Other resources expended|||||3|(344)|||(344)|(245)|
|Share ofoperating result||ofassociates|||12|(304)|||(304)||
|Total ex enditure||||||7,114|38,345|8,039|53498|45,894|
|Net incomel ex enditure||for the|ear|||596|621|6,145|4928|7,054|
|Transfers
and revaluation|||||||||||
|Capital transfers|||||20|(912)||912|||
|Other transfers|||||20|193|(65)|(128)|||
|Net movement
in funds|for the||ear|||1,315|686|6,929|4,928|7,054|
|Total funds brought
forward as|||previously|stated||26,168|794|108,648|135,610|118,782|
|Prior
ear ad'ustment|||||21|||36,100|36100|26,326|
|Funds brought
forward||as restated||||26,168|794|72,548|99,510|92,456|
|Net movement
in funds for the year||||||(1,315)|(686)|6,929|4,928|7,054|
|Funds carried forward|||||20|24,853|108|79,477|104438|99,510|
##
||||||Restated||Restated|
|---|---|---|---|---|---|---|---|
|||||Group|Group|Company|Company|
|||||2023|2022|2023|2022|
||||Note|f000|f000|6000|f000|
|Fixed assets||||||||
|Tangible assets|||10|73,815|66,983|73,815|66,983|
|Intangible
assets|||11|||||
|Investments|||12|||1|1|
|investments
in associates||||||||
|Share of total assets||||1,903|2,590|||
|Share of total liabilities||||(296)|(679)|||
||||12|1,607|1,911|||
|Total fixed assets||||75422|68,894|73816|66,984|
|Current assets||||||||
|Stocks|||13|340|283|340|283|
|Debtors|||14|12,201|13,281|12,067|13,224|
|Cash at bank and
in hand|||15|37,668|42,948|37,444|42,768|
|||||50,209|56,512|49,851|56,275|
|Current
liabilities||||||||
|Creditors: amounts
falling||due within one year|16|(21,193)|(25,612)|(21,096)|(25,495)|
|Total net current assets||||29,016|30,900|28,755|30,780|
|Total assets less current||liabilities||104,438|99,794|102,571|97,764|
|Provisions
for liabilities|and|charges|18||(284)||(284)|
|Total net assets|||19|104438|99,510|102571|97,480|
|The funds ofthe charity||||||||
|Unrestricted
funds||||||||
|Fixed assets reserve|||20|6,770|7,663||5,752|
|Designated
reserves|||20|11,705|12,118||12,118|
|General reserve|||20|6,378|6,387||6,267|
|Total unrestricted
funds||||24,853|26,168||24,137|
|Restricted funds||||||||
|General reserve|||20|108|794|108|794|
|Fixed assets reserve|||20|68,652|61,231|68,653|61,232|
|Designated
reserves|||20|10,825|11,317|10,825|11,317|
|Total restricted
funds||||79,585|73,342|79,586|73,343|
|Total funds|||20|104438|99,510|102571|97,480|
##
||||||||||Restated|
|---|---|---|---|---|---|---|---|---|---|
|||||||||Total|Total|
|||||||||2023|2022|
|||||||||6000|f000|
|Cash flows from operating||activities||||||||
|Net movement
in funds for the year||||||||4,928|7,054|
|Share of operating
result of|associates|||||||304|(261)|
|Net income/(expenditure)
for||the year||||||5,232|6,793|
|Interest receivable||||||||(636)|(118)|
|Depreciation
and amortisation||||||||8,039|4,799|
|Capital grants receivable||||||||(14,184)|(12,184)|
|Loss on disposal of tangible||assets||||||8|175|
|Increase
in stocks||||||||(57)|(25)|
|Decrease in debtors||||||||1,080|4,157|
|Decrease in creditors||||||||(4,419)|(7,801)|
|Decrease in provisions||||||||(284)||
|Net cash used in o eratin||activities||||||5221|4,204|
|Cash flows from investing||activities:||||||||
|Interest received||||||||636|118|
|Purchase of tangible assets||||||||(14,879)|(10,458)|
|Capital grants received||||||||14,184|12,184|
|Proceeds from sale of tangible assets|||||||||93|
|Net cash
used
in
/
rovided
b|||investin||activities|||59|1,937|
|Chan e in cash and cash|e uivalents|||in|the re ortin||cried|5280|2,267|
|Cash and cash equivalents|at the beginnning||||ofthe period|||42,948|45,215|
|Total cash and cash e uivalents|||at the end ofthe|||ear||37668|42,948|
##
##
##
##
##
##
|||||Research|Student|Other|Total|Research|Student|Other|Total|
|---|---|---|---|---|---|---|---|---|---|---|---|
|||||activities|activities|activities|2023|activities|activities|activities|2022|
|||||FOOO|FOOO|f000|FOOO|f000|FOOO|f000|FOOO|
|Grant income||||||||||||
|BBSRC||||25,068|2,953|-|28,021|21,445|3,708||25,153|
|Other government
departments||||1,326|-|-|1,326|1,515|34||1,549|
|European
Union||||2,540|53|-|2,593|3,002|60||3,062|
|Industrial
partners||||224|11|-|235|943|84||1,027|
|John Innes Foundation||||256|451|-|707|142|436||578|
|Other charities||||2,625|211|-|2,836|2,343|142||2,485|
|Universities|||||47||47|27|76||103|
|Other grants||||1,219|-|-|1 219|698|36||734|
|Total
rant income||||33,258|3,726|-|36,984|30,115|4,576||34,691|
|Capital and maintenance||grants||||||||||
|BBSRC||||||||||||
|Capital expenditure||||14,917|||14,917|13,287|||13,287|
|John Innes Foundation||||||||||||
|Capital expenditure|||||||7|133|||133|
|Total ca ital
rants||||14,924|||14,924|13,420|||13,420|
|Other charitable
income||||||||||||
|Scientific services||||||686|686|||633|633|
|Miscellaneous
income||||||142|142|||72|72|
|Total other charitable|income|||||828|828|||705|705|
|Trading
income||||||||||||
|John Innes Enterprises|Limited|||||916|916|||464|464|
|Norwich Biosciences Limited||||||12|12|||27|27|
|Total tradin
income||||||928|928|||491|491|
|Rental income||||||||||||
|Conferencing
Facilties||||||186|186|||64|64|
|Hill House||||||69|69|||77|77|
|Total rental income||||||255|255|||141|141|
|Investment
income||||||||||||
|Interest receivable
on cash||deposits||||629|629|||111|111|
|Interest receivable
on loan||to related|party|||7|7|||7|7|
|Total investment
income||||||636|636|||118|118|
|Income from investment|in|associates||||||||261|261|
|Total associates income||||||||||261|261|
|Other generated
income||||||||||||
|Site infrastructure
recharges||||||2,005|2,005|||1,520|1,520|
|Other||||||1,866|1,866|||1,601|1,601|
|Total other
enerated|income|||||3,871|3,871|||3,121|3,121|
|Total income||||48,182|3,726|6,518|58,426|43,535|4,576|4,837|52,948|
##
##
|||||||||||||Restated|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
||||||Research|Student|Other|Total|Research|Student|Other|Total|
||||||activities|activities|activities|2023|activities|activities|activities|2022|
|||||Note|OOOO|OOOO|L'000|OOOO|OOOO|L'000|OOOO|KOOO|
|Direct charitable|expenditure:||||||||||||
|Staff costs|||||13,116|||13,116|13,639|||13,639|
|Direct costs|||||12,580|4,196|-|16,776|11,719|3,764||15,483|
|Depreciation
and|impairment||||8,039|-|-|8,039|4,799|||4,799|
|Governance
costs||||4|||105|105|||107|107|
|Support costs||||4|10,750|2,933|-|13,683|8,128|2,544||10,672|
|Expenditure
on|charitable||activities||44,485|7,129|105|51,719|38,285|6,308|107|44,700|
|Raising funds|||||||439|439|||370|370|
|Trading
expenditure|||||||692|692|||579|579|
|Other resources|expended||||||344|344|||245|245|
|Share of operating||result of|associates||||304|304|||||
|Total ex
nditure|||||44,485|7,129|1,884|53,498|38,285|6,308|1,301|45,894|
||||Total|Total|
|---|---|---|---|---|
|Ana|sis of|overnance costs|2023|2022|
||||6000|OOOO|
|Staff|costs||46|35|
|Travel|costs||12|2|
|Other|costs||47|70|
|Total|overnance costs||105|107|
##
|4.
ALLOCATIO|N
O|F SUPPORT C|OSTS, GOV|ERNANCE|AND|RAISING F|UNDS||
|---|---|---|---|---|---|---|---|---|
||||Research|Student|Raising|Governance|Total|Basis of|
||||activities|activities|funds|costs|2023|Allocation|
||||6000|6000|5000|6000|OOOO||
|Governing
Council and|SIAB|||||60|60|Headcount|
|Lab management|||425|116|||541|Headcount|
|Institute
management|||337|92|||429|Headcount|
|Scientific services|||365|100|||465|Headcount|
|Facilities management|and utilities*||7,602|2,074|||9,676|Headcount|
|Finance and Purchasing"|||538|147|||685|Headcount|
|Computing
and Library*|||635|173|||808|Headcount|
|Human
Resources*|||267|73|||340|Headcount|
|Contracts services*|||||314||314|Activity|
|Other support services|||581|158|125||909|Activity|
|Total su
ort costs|||10,750|2,933|439|105|14,227||
||||Research|Student|Raising|Governance|Total|Basis of|
||||activities|activities|funds|costs|2022|Allocation|
||||OOOO|OOOO|FOOO|FOOO|FOOO||
|Governing
Council and|SIAB|||||68|68|Headcount|
|Lab management|||393|123|||516|Headcount|
|Institute
management|||382|120|||502|Headcount|
|Scientific services|||93|29|||122|Headcount|
|Facilities management|and utilities*||5,469|1,711|||7,180|Headcount|
|Finance and Purchasing*|||504|158|||662|Headcount|
|Computing
and Library*|||567|178|||745|Headcount|
|Human
Resources*|||262|82|||344|Headcount|
|Contracts services*|||||277||277|Activity|
|Other support services|||458|143|93||733|Activity|
|Total su
ort costs|||8 128||370|107|11149||
|*Includes services supplied||by NBI Partnership|Limited (see|note 23). Scientific services costs are shown net||||ofrecharges to|
|science projects.|||||||||
##
##
|||||||||Restated|
|---|---|---|---|---|---|---|---|---|
||||||||Total|Total|
||||||||2023|2022|
||||||||f000|f000|
|Audit services:|||||||||
|Fees payable to the charitable|company's|auditors for|the audit of|charitable|company|and|||
|consolidated
financial
statements|||||||31|29|
|Fees payable for the audit of|the charitable|company's|subsidiaries|pursuant|to legislation||1|1|
|Depreciation
and amortisation|||||||8,039|4,799|
|Loss on disposal of tangible assets|||||||8|175|
|Hire of plant and equipment|||||||63|65|
|Rent of land and buildings|||||||41|33|
|(Profit) on foreign exchange translations|||||||(120)|(18)|
##
|||||John Innes|Norwich||John Innes|Norwich||
|---|---|---|---|---|---|---|---|---|---|
|||||Enterprises|Biosciences|Total|Enterprises|Biosciences|Total|
|Profit and|loss account|||Limited|Limited|2023|Limited|Limited|2022|
|||||f000|6000|6000|6000|6000|6000|
|Turnover||||916|12|928|464|27|491|
|Cost of sales||||731||731|579||579|
|Gross profit/(loss)||||185|12|197|(115)|27|(88)|
|Administrative
e
enses||||||||||
|Operating|profit/(loss)|||185|12|197|(115)|27|(88)|
|Interest received||||||||||
|0 eratin|refit/ loss|retained|in subsidiar|185|12|197|115|27|88|
|Net assets|at 31 March|||258|||73||117|
##
##
##
|Grou|and charitable|com|com|an||2023|2022|
|---|---|---|---|---|---|---|---|
|||||||Number|Number|
|Scientific||||||328|347|
|Office|mana
ement and||services|||35|31|
|Total|||||||378|
|The aggregate
payroll|||costs ofthese persons were:|||||
|Grou|and charitable|com||n||2023|2022|
||||||Note|fOOO|f000|
|Wages|and salaries|||||13,664|13,702|
|Redundancy
costs||||||11|43|
|Social|security costs|||||1,463|1,393|
|Other|ension costs||||23|1,894|2,007|
|Total||||||17032|17,145|
|An analysis ofthe number ofstaff who fall within staff cost bands (ex|cluding
pension cost) from f60k upwards
is provid|ed
below|
|---|---|---|
|Grou
and charitable com an|2023|2022|
||Number|Number|
|f60,000 - f69,999|20|16|
|f70,000 - f79,999|11|7|
|f80,000 - f89,999|4|9|
|f90,000 - f99,999|7|7|
|f100,000 - f109,999|5|2|
|f110,000 - f119,999|2|3|
|f120,000 - f129,999||1|
|f130,000 - f139,999|||
|f140,000 - f149,999|||
|f150,000 - f159,999|||
|f160,000 - f169,999|||
|f170,000 - f179,999|||
|f220,000 - f229,999|||
|Total|55|49|
##
##
##
|10.TANGIBLE ASS|ETS||||||||
|---|---|---|---|---|---|---|---|---|
|||||Long||Plant,|||
||||Freehold|leasehold|machinery||Assets||
||||land and|land and||and|under|Restated|
|Grou
6Com
an||Note|buildin s|buildin
s|e|ui
ment|construction|Total|
||||f000|LOOO||LOOO|f000|6000|
|Cost/Valuation|||||||||
|Brought forward as previously|stated||3,771|72,318||52,972|2,371|131,432|
|Prior
ear ad'ustment||21||4,822||||4 822|
|Restated at 1 April 2022|||3,771|67,496||52,972|2,371|126,610|
|Transfers|||49|118||1,989|(2,156)||
|Additions||||418||7,499|6,962|14,879|
|Dis osals||||||797|8|805|
|At 31 March 2023|||3,820|68,032||61,663|7,169|140,684|
|Accumulated
Depreciation|||||||||
|Brought forward as previously|stated||824|||27,525||28,349|
|Prior
ear ad'ustment||21||31,278||||31278|
|Restated at 1 April 2022|||824|31,278||27,525||59,627|
|Charge for the year|||5|2,622||5,412||8,039|
|Dis osals||||||797||797|
|At 31 March 2023|||829|33900||32140||66869|
|Net book value at 31 March|2023||2 991|34132||29523|7 169|73815|
|Restated
net book value at 31|March 2022||2,947|36,218||25,447|2,371|66,983|
##
##
|||Registration|Country of|||||||Class and percentage|Class and percentage|of|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Subsidia|Undertakin|number|re istration|Princi
al activit||||||shares held|||
|John Innes Enterprises
Limited||02549904|England|Contract research||||||100%ordinary|shares||
|Norwich|Biosciences Limited|03076575|England|Management
of|intellectual|||property||100%ordinary|shares||
|Norwich|Research
Limited|02814101|England|Dormant||||||100%ordinary|shares||
|JIC NRP|Capital
Limited|06145922|England|Member ofAnglia||Innovation||Partnership|LLP|100%ordinary|shares||
|The registered
address for all the subsidiaries
is John||||innes Centre,|Norwich||Research Park, Colney,|||Norwich,
NR4|7UH.||
##
##
##
##
##
|The move|ment
in the value of investments
during the year was as follows:|||
|---|---|---|---|
|||Total|Total|
|||2023|2022|
|||6000|f000|
|Valuation||||
|At beginning|of year|||
|Acquisition||||
|Im airment||||
|Atend of|ear|||
|Historical cost||||
|As at 1|rll 2022 and 31 March 2023|1 631|1,631|
##
||||||Leaf|||Leaf|||
|---|---|---|---|---|---|---|---|---|---|---|
||||||Expression|Plant||Expression|Plant||
||||||Systems|Bioscience|Total|Systems|Bioscience|Total|
|Grou|||||Limited|Limited|2023|Limited|Limited|2022|
||||||f000|OOOO|f000|f000|OOOO|OOOO|
|Associates,|share of:||||||||||
|Turnover||||||391|391||1,237|1,237|
|Operating
(loss)/profit||||||(233)|(233)||261|261|
|Movement
in o enin||balance||||71|71||||
|Share of result for the|||ear|||304|304||261|261|
|The Group's|investment||in associates|is represented|as follows:||||||
||||||Leaf|||Leaf|||
||||||Expression|Plant||Expression|Plant||
||||||Systems|Bioscience|Total|Systems|Bioscience|Total|
|Grou|||||Limited|Limited|2023|Limited|Limited|2022|
||||||f000|f000|6000|f000|f000|OOOO|
|Associates:|Share of|net assets|||||||||
|At beginning|of year|||||1,911|1,911||1,650|1,650|
|Additions|||||||||||
|Impairment|provision||||||||||
|Share of result for the|||ear|||304|304||261|261|
|At end of|ear|||||1,607|1 607||1,911|1 911|
|Represented|by:||||||||||
|Share of total assets||||||1,903|1,903||2,590|2,590|
|Share of total liabilities||||||296|296||679|679|
|Share of net assets||||||1,607|1 607||1,911|1 911|
##
|||||Total|Total|
|---|---|---|---|---|---|
|Grou|and charitable||com an|2023|2022|
|||||6000|f000|
|Raw|materials|and consumables||340|283|
|Total||||340|283|
##
##
||||||||Group|Group|Company|Company|
|---|---|---|---|---|---|---|---|---|---|---|
||||||||2023|2022|2023|2022|
|||||||Note|6000|f000|6000|f000|
|Grants receivable:|||||||||||
|from government||bodies||||24|2,187|4,219|2,187|4,219|
|from other sources|||||||2,684|2,467|2,684|2,467|
|Trade debtors|||||||2,764|1,465|2,418|1,297|
|Amounts
owed|by|subsidiary||undertakings|||||253|139|
|Amounts
owed|by|other|related parties|||24|951|1,054|942|1,054|
|Other debtors|||||||559|961|559|934|
|Pre a ments and||accrued||income|||3056|3,115|3024|3,114|
|Total amounts|fallin||due|within one|ear||12201|13,281|12067|13,224|
##
|15.|C|ASH AT BANK AND IN HAND|||||
|---|---|---|---|---|---|---|
||||Group|Group|Company|Company|
||||2023|2022|2023|2022|
||||6000|f000|6000|f000|
|Cash|at|bank|37,666|42,945|37,442|42,765|
|Cash|in|hand|2|3|2|3|
|Total|||37668|42,948|37444|42,768|
##
||||||Group|Group|Company|Company|
|---|---|---|---|---|---|---|---|---|
||||||2023|2022|2023|2022|
|||||Note|6000|f000|6000|f000|
|Grants received in advance:|||||||||
|from government
bodies||||24|5,345|6,285|5,345|6,285|
|from other sources|||||3,995|4,576|3,958|4,493|
|Trade creditors|||||3,686|3,475|3,686|3,464|
|Amounts
owed to subsidiary||undertakings|||||1||
|Amounts
owed to other|related parties|||24|896|1,107|896|1,107|
|Other creditors|||||1,210|1,838|1,148|1,829|
|Taxation and social security|||||353|369|353|369|
|Accruals and deferred|income||||5708|7,962|5709|7,948|
|Total amounts
fallin|due|within one|ear||21 193|25,612|21 096|25,495|
##
|||||||Total|Total|
|---|---|---|---|---|---|---|---|
|Grou|and charitable|com an||||2023|2022|
||||||Note|6000|OOOO|
|Grants|receivable||||14|4871|6 686|
|Grants|received
in advance||||16|9340|10,861|
|Net|rants received|in advance||||4469|4,175|
|Net grants received
in||advance at beginning||ofyear||(4,175)|(2,722)|
|Grant|monies received|during
the year||||(52,202)|(49,564)|
|Grant|mone
released|to SOFA durin|the|ear||51908|48,111|
|Net|rants received|in advance||||4,469|4,175|
##
##
|||||Total|Total|
|---|---|---|---|---|---|
|Grou
and charitable||com an||2023|2022|
|||||f000|f000|
|Restructuring
provision||at beginning|ofyear||284|
|Charge
in|the year|||||
|Released|in the year|||(284)||
|Nilised||||||
|Provision|at end of|ear|||284|
##
||||Fixed|Net current|Total|
|---|---|---|---|---|---|
||||assets|assets|2023|
||||f000|f000|6000|
|Group||||||
|Unrestricted:||||||
|Fixed assets||reserve|6,770||6,770|
|Designated||capital reserve||11,705|11,705|
|General||||6,378|6,378|
|Restricted:||||||
|General reserve||||108|108|
|Fixed assets||reserve|66,652||68,652|
|Designated||capital reserve||10,825|10,825|
|Net assets|||75422|29016|104438|
|Charitable|company|||||
|Unrestricted:||||||
|Fixed assets||reserve|5,163||5,163|
|Designated||capital reserve||11,705|11,705|
|General||||6,117|6,117|
|Restricted:||||||
|General reserve||||108|108|
|Fixed assets||reserve|68,653||68,653|
|Designated||capital reserve||10,825|10,825|
|Net assets|||73816|28 755|102571|
##
##
||||||Creditors||
|---|---|---|---|---|---|---|
||||||over one|Restated|
||||Fixed|Net current|year and|Total|
||||assets|assets|rovisions|2022|
||||f000|FOOO|f000|6000|
|Group|||||||
|Unrestricted:|||||||
|Fixed assets||reserve|7,663|||7,663|
|Designated||capital reserve||12,118||12,118|
|General||||6,671|(284)|6,387|
|Restricted:|||||||
|General reserve||||||794|
|Fixed assets||reserve|61,231|||61,231|
|Designated||capital reserve||11,317||11,317|
|Net assets|||68894|30900|284|99510|
|Charitable|company||||||
|Unrestricted:|||||||
|Fixed assets||reserve|5,752|||5,752|
|Designated||capital reserve||12,118||12,118|
|General||||6,551|(284)|6,267|
|Restricted:|||||||
|General reserve||||||794|
|Fixed assets||reserve|61,232|||61,232|
|Designated||capital reserve||11,317||11,317|
|Net assets|||66984|30780|284|97480|
##
##
||Unrestricted|||||Restricted||||
|---|---|---|---|---|---|---|---|---|---|
||fixed|Unrestricted||Unrestricted|Restricted|fixed|Restricted||Total|
||assets|designated||general|general|assets|designated||2023|
||FOOO||FOOO|OOOO|FOOO|FOOO||FOOO|OOOO|
|Group||||||||||
|At 1 April 2022|7,663||12,118|6,387|794|61,231||11,317|99,510|
|Total income and expenditure|for the year|||(596)|(621)|6,145|||4,928|
|Associates|(304)|||304||||||
|Capital transfers|(920)|||||1,284||(364)||
|Centre funded
capital|331||(331)|8||(8)||||
|Other transfers|||82|275|65|||128||
|At 31 March 2023|6,770||11,705|6,378|108|68,652||10,825|104438|
|Charitable
company||||||||||
|At 1 April 2022|5,752||12,118|6,267|794|61,232||11,317|97,480|
|Total income and expenditure|for the year|||(514)|(540)|6,145|||5,091|
|Capital transfers|(920)|||||1,284||(364)||
|Centre funded
capital|331||(331)|8||(8)||||
|Other transfers|||82|356|146|||128||
|At 31 March 2023|5,163||11,705|6,117|108|68,653||10,825|102571|
||Unrestricted|||||Restricted|||Restated|
||fixed|Unrestricted||Unrestricted|Restricted|fixed|Restricted||Total|
||assets|desi|nated|eneral|eneral|assets|desi|nated|2022|
||FOOO||FOOO|f000|f000|FOOO||FOOO|FOOO|
|Group||||||||||
|At 1 April 2021|7,994||12,645|7,266|48|55,248||9,255|92,456|
|Total income and expenditure|for the year|||274|(605)|7,385||-|7,054|
|Associates|261|||(261)||||||
|Capital transfers|(624)||||(36)|660||||
|Centre funded
capital|32||(300)|268||(2,062)||2,062||
|Other transfers|||227|1,160|1,387|||||
|At 31 March 2022|7,663||12,118|6,387|794|61,231||11,317|99510|
|Charitable
company||||||||||
|At 1 April 2021|6,344||12,645|7,028|48|55,486||9,255|90,806|
|Total income and expenditure|for the year|||159|(633)|7,148|||6,674|
|Capital transfers|(624)||||(36)|660||||
|Centre funded
capital|32||(300)|268||(2,062)||2,062||
|Other transfers|||227|1,188|1,415|||||
|At 31 March 2022|5,752||12,118|6,267|794|61,232||11,317|97480|
##
##
##
##
|||||||Restated|
|---|---|---|---|---|---|---|
||||||Total|Total|
|Grou
and charitable
com an|||||2023|2022|
||||||f000|f000|
|Capital commitments||at the end of|the financial year for which no provision|has been made:|||
|Contracted|||||5382|5,031|
|Amounts|due under|other operating|leases for plant and machinery:||||
|Expiring|in less than one year||||44|36|
|Expiring|between|one and two years|||28|32|
|Expiring|betveen|two and five years|||13|16|
|E
irin|over five|ears|||2||
||||||87||
##
##
##
##
##
##
##
##
##
##
##
|IF is a mem
ransactions|ber ofthe charitable
company
and
it nominates
one Go
took place during the year:|vernor to the Governing
Council ofJIC. The follow|ing|
|---|---|---|---|
||||Restated|
|||Total|Total|
|||2023|2022|
|||OOOO|f000|
|Paid toJIC:||||
|Grants for studentships||471|436|
|Grants for research project||150|142|
|Contribution|to salary costs|27|39|
|Contribution|to other costs|52|3|
|Contribution|to ca ital costs|7|133|
|||707|753|
##
##
##
##
##
##